Vor Biopharma Inc. Operating Cash Flow
Vor Biopharma Inc. (VOR) reported Operating Cash Flow of -$63.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Vor Biopharma Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$25.38M.
- Vor Biopharma Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$38.25M.
- Vor Biopharma Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$22.80M.
- Vor Biopharma Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$53.66M.
- Vor Biopharma Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$142.71M.
- Vor Biopharma Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$99.66M.
- Vor Biopharma Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$100.29M.
- Vor Biopharma Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$85.14M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$25.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$63.62M 10-Q · filed 2026-08-11 | -$86.42M derived: sum of 3 quarters · filed 2026-08-11 | -$140.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$38.25M 10-Q · filed 2026-05-13 | -$61.05M derived: sum of 2 quarters · filed 2026-05-13 | -$114.71M derived: sum of 3 quarters · filed 2026-05-13 | -$149.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$22.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$76.46M derived: sum of 2 quarters · filed 2026-03-30 | -$111.65M derived: sum of 3 quarters · filed 2026-08-11 | -$142.71M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$53.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$88.85M derived: sum of 2 quarters · filed 2026-08-11 | -$119.91M 10-Q · filed 2025-11-13 | -$143.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$35.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$66.25M 10-Q · filed 2026-08-11 | -$90.31M derived: sum of 3 quarters · filed 2026-08-11 | -$113.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$31.07M 10-Q · filed 2026-05-13 | -$55.13M derived: sum of 2 quarters · filed 2026-05-13 | -$78.41M derived: sum of 3 quarters · filed 2026-05-13 | -$100.26M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$24.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$47.35M derived: sum of 2 quarters · filed 2026-03-30 | -$69.19M derived: sum of 3 quarters · filed 2026-03-30 | -$99.66M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$23.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$45.13M derived: sum of 2 quarters · filed 2025-11-13 | -$75.60M 10-Q · filed 2025-11-13 | -$99.62M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$21.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$52.31M 10-Q · filed 2025-08-12 | -$76.34M derived: sum of 3 quarters · filed 2025-08-12 | -$104.24M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$30.46M 10-Q · filed 2025-05-14 | -$54.49M derived: sum of 2 quarters · filed 2025-05-14 | -$82.39M derived: sum of 3 quarters · filed 2025-05-14 | -$106.49M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$24.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$51.92M derived: sum of 2 quarters · filed 2025-03-20 | -$76.02M derived: sum of 3 quarters · filed 2025-03-20 | -$100.29M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$27.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$52.00M derived: sum of 2 quarters · filed 2024-11-07 | -$76.27M 10-Q · filed 2024-11-07 | -$94.61M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$24.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$48.37M 10-Q · filed 2024-08-08 | -$66.71M derived: sum of 3 quarters · filed 2024-08-08 | -$85.62M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$24.27M 10-Q · filed 2024-05-09 | -$42.61M derived: sum of 2 quarters · filed 2024-05-09 | -$61.52M derived: sum of 3 quarters · filed 2024-05-09 | -$86.51M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$18.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$37.25M derived: sum of 2 quarters · filed 2024-03-20 | -$62.24M derived: sum of 3 quarters · filed 2024-03-20 | -$85.14M 10-K · filed 2024-03-20 |
| 2022-09-30 | -$18.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$43.89M derived: sum of 2 quarters · filed 2023-11-07 | -$66.80M 10-Q · filed 2023-11-07 | -$84.39M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$24.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$47.90M 10-Q · filed 2023-08-10 | -$65.48M derived: sum of 3 quarters · filed 2023-08-10 | -$82.83M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$22.90M 10-Q · filed 2023-05-11 | -$40.49M derived: sum of 2 quarters · filed 2023-05-11 | -$57.83M derived: sum of 3 quarters · filed 2023-05-11 | -$74.40M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$17.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$34.93M derived: sum of 2 quarters · filed 2023-03-23 | -$51.49M derived: sum of 3 quarters · filed 2023-03-23 | -$69.14M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$17.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$33.91M derived: sum of 2 quarters · filed 2022-11-10 | -$51.56M 10-Q · filed 2022-11-10 | -$65.19M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$16.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$34.21M 10-Q · filed 2022-08-11 | -$47.85M derived: sum of 3 quarters · filed 2022-08-11 | -$56.09M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$17.65M 10-Q · filed 2022-05-12 | -$31.28M derived: sum of 2 quarters · filed 2022-05-12 | -$39.53M derived: sum of 3 quarters · filed 2022-05-12 | -$47.86M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$13.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | -$21.88M derived: sum of 2 quarters · filed 2022-03-14 | -$30.21M derived: sum of 3 quarters · filed 2022-03-14 | -$36.29M 10-K · filed 2022-03-14 |
| 2020-09-30 | -$8.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$16.57M derived: sum of 2 quarters · filed 2021-11-10 | -$22.66M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$8.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$14.41M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$6.08M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |